Rein Bio: Advance control change and transactions such as issuance of shares to purchase assets.

Rhein Biotech announced that on December 22, 2025, the original controlling shareholder Qin Benjun signed an agreement with Guangzhou Defu Nutrition to transfer 60 million shares, abandon 189 million voting rights, and Guangzhou Defu Nutrition will become the controlling shareholder. Hou Ming and LIZHENFU become the joint actual controllers. The company plans to issue shares to purchase 80% equity of Beijing Jinkangpu and raise supporting funds. The stock will be suspended from trading on December 10, 2025, and resume trading on December 24, 2025. As of the disclosure date of the announcement, the earnest money for the share transfer has been paid and confirmed, and the audit, evaluation, and other work is steadily progressing. The transaction still requires multiple approvals, and there are uncertainties.